Non-steroidal anti-Inflammatory drugs (NSAIDs) exhibit antineoplastic properties, but conventional NSAIDs do not fully meet safety and efficacy criteria for use as anti-cancer agents. In this study, we evaluated the chemotherapeutic efficacy of five novel phospho-NSAIDs, each of which includes in addition to the NSAID moiety a diethylphosphate linked through a butane moiety. All five compounds inhibited the growth of human breast, colon and pancreatic cancer cell lines with micromolar potency. In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, where cell proliferation was suppressed and apoptosis enhanced in the absence of detectable animal toxicity. Notably, all of the phospho-NSAIDs tested induced reactive oxygen and nitrogen species in cultured cells, with PA and PS inducing detectable levels of oxidative stress in vivo that were associated positively with apoptosis and negatively with proliferation. Potentially explaining these effects, all of the phospho-NSAIDs tested also inhibited the thioredoxin system and the redox sensitive transcription factor NF-κB. Taken together, our findings demonstrate the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon and pancreatic cancer, suggesting further evaluation as anticancer agents..
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used anti-inflammatory compounds, with aspirin, the prototypical NSAID, being one of the oldest and still most extensively used medications in the world (1, 2) . NSAIDs have a significant antineoplastic effect, which is currently viewed in the context of the recently appreciated role of inflammation in cancer (3) . Interventional studies have established aspirin and sulindac as chemopreventive agents against colon cancer (4, 5) . For the remaining NSAIDs, the evidence of their chemopreventive properties strong as it is, is mainly based on epidemiological studies (4, 6, 7) . For example, a meta-analysis of 91 epidemiological studies showed a significant exponential decline with increasing intake of NSAIDs in the risk for 7-10 malignancies including the four major types: colon, breast, lung, and prostate cancer (8, 9) . However, there is no chemotherapeutic application for aspirin or other NSAIDs in humans or animals. Only sulindac when combined with other anticancer agents is reported to have a chemotherapeutic effect in mice (10).
NSAIDs prevent cancer likely through pleiotropic effects reviewed in (11) (12) (13) ). Although their bestrecognized molecular target is the enzyme cyclooxygenase (COX), there is considerable evidence that such an effect may not be required for their anticancer actions (14, 15) . Regardless of mechanistic issues, it is clear that conventional NSAIDs do not meet the criteria of safety and efficacy for their application as anti-cancer agents. NSAIDs are associated with considerable side effects, and their chemoprevention efficacy is rather limited, at best not exceeding 50% (16) . Thus, there is a need to develop compounds with improved efficacy and safety.
Prompted by these considerations, we synthesized a series of compounds based on four representative NSAIDs, aspirin, sulindac (2 derivatives, differing in the structure of the sulindac moiety), ibuprofen, and flurbiprofen (Suppl. Fig. 1 ). Each one of these NSAIDs is chemopreventive against at least one major type of cancer based either on preclinical or epidemiological data (7, 8, 17, 18) . Structurally, these five compounds belong to a broader class of novel compounds that we have synthesized, which conform to the general chemical formula A-aliphatic linker-DEP, where A can be any compound, the linker can vary in size and/or structure as long as it is aliphatic, and DEP= diethylphosphate. Here, we report on compounds where A=NSAID moiety and the linker is a moiety derived from 1,4-butane diol. Of note, the enhanced safety of the phospho-NSAIDs is attributed in part to this chemical modification, since the carboxylic group, present in nearly all NSAIDs, mediates much of their gastrointestinal toxicity (19) .
Phospho-sulindac (PS; OXT-328), phospho-aspirin (PA; MDC-118) and phospho-ibuprofen (PI; MDC-917) are highly effective against inflammation, as shown in a rat arthritis model (20) . All three had a favorable safety profile, especially concerning gastrointestinal toxicity (20, 21) . Recently, PS was found in preclinical models of colon cancer to be strongly chemopreventive and chemotherapeutic. For example, in combination with difluoromethylornithine, PS prevented 91% of intestinal tumors in Min mice (21) and PS alone inhibited the growth of human colon xenografts in nude mice by 70% (22) .
In the present study, we evaluated the chemotherapeutic potential of these five compounds against breast, colon, and pancreatic cancer using human cancer xenografts. All displayed a significant anticancer effect, which was mediated, at least to some extent, by a redox effect that likely affected major downstream signaling pathways.
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MATERIALS AND METHODS

Reagents
Phospho-NSAIDs, synthesized following the methodology of Penning et al (23) , were provided by Medicon Pharmaceuticals, Inc, Setauket, NY. The lipids for the preparation of liposomes were from Avanti Phospholipids (Alabaster, AL). For each compound we prepared a 100 mM stock solution in DMSO. In all cell culture media, the final DMSO concentration was adjusted to 1%. All general solvents and reagents were of HPLC grade or of the highest grade commercially available.
Cell culture
Human breast (MCF-7 and MDA-MB 231), colon (HT-29, and SW480) and pancreatic (MIA PaCa-2 and BxPC-3) cell lines were obtained from American Type Culture Collection (Manassas, VA) and were grown in the specific medium and conditions suggested by ATCC. All the cell lines were passaged in our laboratory for less than 6 months after receipt.
Cell viability assay
Following treatment with various concentrations of phospho-NSAIDs for 24 h, the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye (MTT), was determined according to the manufacture's protocol (Promega, Madison, WI, USA).
Cell kinetics analysis
5-bromo-2′-deoxyuridine (BrdU) incorporation into newly synthesized cellular DNA was used to determine cell proliferation as described (24) . For apoptosis, 1.0×10 5 cells/well were treated with phospho-NSAIDs for 24 h, trypsinized, stained with Annexin V-FITC (100X dilution, Invitrogen) and PI (0.5 µg/ml, Sigma) and analyzed by FACScaliber (BD Bioscience). Cell cycle progression was analyzed by flow cytometry as described (24) .
Determination of reactive oxygen and nitrogen species (RONS)
After treatment, cells were collected by trypsinization, resuspended in 10 μM of 5-(and-6)-carboxy-2',7'-dichlorofluorescine diacetate (DCFDA; Invitrogen, Carlsbad, CA), incubated at 37 °C for 30 min in the dark and their fluorescence intensity was determined by flow cytometry (Beckman Coulter Inc., Fullerton, CA). We analyzed a minimum of 10,000 events using the WinMDI software and expressed the data as the fluorescent intensity versus events.
Determination of TrxR reductase activity
After treatment, cells were lysed and TrxR activity was determined in the protein lysate using a commercially available kit, following the instructions of the manufacturer (Cayman Chemical). In this assay, TrxR uses NADPH to reduce 5,5′-dithiobis-(2-nitrobenzoic acid) to 5-thio-2-nitrobenzoic acid (TNB).
Protein extraction from whole cell lysates
After treatment, cells were scraped on ice, washed with ice-cold phosphate-buffered saline (PBS) and lysed in RIPA lysis buffer (Sigma, St Louis, MO). Protein concentration was determined using the Bradford method (Bio-Rad, Hercules, CA).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear fractions were isolated from 2x10 6 cells (treated and controls) and subjected to EMSA as previously described (24) .
Liposome-PI
PI was loaded onto PEGylated liposomes, following standard protocols (25, 26 
Immunohistochemistry
Immunohistochemical staining for Ki-67, TrxR and phospho-NF-κB (activated form of NF-κB) was performed on human breast, colon and pancreatic xenograft tissue samples as previously described (27) . were considered unlabelled, while those with a brown nucleus (or brown cytoplasma in the case of TrxR)
were considered labeled. We calculated the percentage of proliferating and apoptotic cells by dividing the number of labeled cells by the number of cells in each field and multiplying by 100.
Statistical analyses
Results are expressed as Mean ± SEM. Differences between groups were determined by one-factor analysis of variance followed by Tukey's test for multiple comparisons and the association between data sets by correlation analysis and computing the correlation coefficient (R). p<0.05 was statistically significant.
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on October Table 1 shows key genotypic features of each cell line and the 24-h IC 50 of these compounds, which range from 17 to 303 µM. It seems that the growth inhibition potency of these compounds was independent of the tissue of origin, receptor status or COX expression of these cell lines.
We then determined the effect of PA, PS and PI on the growth of breast, colon and pancreatic human cancer xenografts in athymic nude mice ( inhibition, p<0.01-0.05) maintaining tumor stasis throughout the treatment period. Underscoring the significance of the drug delivery method, the mouse plasma level of PI was 3.5-fold higher in Lipo-PI compared to PI (data not shown). Of note, the liposomal formulation of PI had a minimal effect on its in vitro IC 50 (Suppl Fig. 2 ).
Consistent with our previous findings (20, 21) , none of the animals showed any signs of toxicity from the phospho-NSAIDs, including weight loss or distress. In addition, on autopsy at sacrifice there were no signs of GI bleeding, or gastrointestinal, pancreatic, renal or liver damage.
The cytokinetic effect of phospho-NSAIDs in vitro and in vivo
To understand the mechanism by which these compounds inhibited cell and tumor growth, we evaluated their effect on cell kinetics in both cancer cells and xenografts.
Inhibition of cell proliferation:
At their IC 50 , the five phospho-NSAIDs inhibited the proliferation of MDA-MB-231 breast cancer cells 37-87% compared to controls, with PS being the most and PA the least potent. Similar results were obtained in BxPC-3 human pancreatic cells. The phospho-NSAIDs also inhibited cell proliferation in xenografts from these cell lines by 29% -59%, except for plain PI, whose effect (13% reduction) was not statistically significant and contrasted to that of Lipo-PI. These results are shown in Table 2A , Fig. 2A , Suppl. Table 1 and Suppl. Fig. 3 .
Induction of apoptosis:
We distinguished two stages of apoptosis, discernible by flow cytometry, namely "early apoptosis," in which the cells are viable (they exclude propidium iodide) and "late apoptosis," known also as secondary necrosis, in which the cells cannot exclude propidium iodide.
The main findings in MDA-MB-231 cells are: a) late apoptosis predominates; b) PI had the strongest and PA the weakest pro-apoptotic effect; and c) despite their minimal structural differences, PDS was more potent than PS. Of note, PI evaluated in BxPC-3 cells had similar effects. In breast, colon and pancreatic xenografts PA, PS and PI induced apoptosis significantly, ranging between 71% and 171% over controls.
These results are shown in Table 2A , Fig. 2B , Suppl. Table 1 and Suppl. Fig. 4 .
Induction of necrosis:
All five compounds induced necrosis modestly, not exceeding 7.2% of the total number of MDA-MB-231 cells (Suppl. Table 1) . As with apoptosis, PI was the most potent inducer of cell necrosis, generating similar results in BxPC-3 cells (Suppl. Fig. 4A ).
Induction of cell cycle arrest: All compounds inhibited the G 1 to S cell cycle phase transition in MDA-MB-231 cells, except for PS, which arrested the G 2 /M phase transition (Suppl. Fig. 5A, B) . Similar effects were obtained in BxPC-3 cells treated with PI (Suppl. Fig. 5C ).
Induction of reactive oxygen and nitrogen species (RONS): Correlation with cytokinetic changes
RONS play a crucial role in the mechanism of action of several anticancer agents (29) (30) (31) . We determined the effect of phospho-NSAIDs on the intracellular levels of RONS using the general RONS A similar effect was documented in vivo, by measuring the urinary levels of F2-isoprostane in mice; F2-isoprostane is a marker of oxidative stress (32, 33) . As shown in Fig. 3B and Table 2B , PA and PS increased the levels of urinary F2-isoprostane in mice with MDA-MB-231 and HT-29 xenografts between 53 and 338% compared to the corresponding controls (all changes were statistically significant). We then assessed whether the induction of oxidative stress by phospho-NSAIDs correlated with the cytokinetic changes induced by these compounds in the xenografts (Fig. 3B) . In both MDA-MB-231 and HT-29 xenografts, the urinary F2-isoprostane levels were positively associated with the percentage of apoptotic cells (R=0.824, p<0.01 and R=0.720, p<0.02, respectively) and negatively associated with the percentage of proliferating cells (R=-0.78, p<0.01 and R=-0.60, p<0.05, respectively; data not shown). These findings suggest a potential etiological connection between oxidative stress and the cytokinetic changes in tumor xenografts that underlie the antitumor effect of the phospho-NSAIDs.
Phospho-NSAIDs inhibit the thioredoxin system
A critical redox modulator in the cells is the thioredoxin system (34). We have shown that the thioredoxin system could mediate redox-induced cell death in response to various anticancer agents (31).
Trx-1, overexpressed in human cancers, has been linked to aggressive tumor growth, inhibition of apoptosis, and decreased patient survival (35) . In cultured MDA-MB-231, the phospho-NSAIDs decreased the expression of Trx-1 (Fig. 4A) . The effect of phospho-NSAIDs on Trx-1 expression in xenografts was variable. In BxPC-3 xenografts, Lipo-PI decreased Trx-1 expression levels by 61.6% (p<0.001) but plain PI failed to do so, in keeping with its lack of antitumor effect (Suppl. Fig. 6B ). PA and PS also decreased Trx-1 expression in MDA-MB-231 xenografts by 75% and 63%, respectively (p<0.05 for both) (Fig. 4A) . However, in HT-29 xenografts PS did not decrease Trx-1 levels, determined both by immunoblotting of tissue extracts and immunohistochemistry (Suppl. Fig. 6C ).
TrxR, overexpressed in many cancers and associated with drug resistance, represents a key drug target (36) . Thus, we determined the activity of TrxR in cultured breast, colon and pancreatic cancer cells treated with our phospho-NSAIDs. As shown in Fig. 4B , in MDA-MB-231, BxPC-3 and HT-29 cells, our five phospho-NSAIDs reduced TrxR activity by 53%-84%, compared to controls (statistically significant for all). PA and PS also decreased the expression of TrxR in MDA-MB-231 xenografts by 43%, and 51%.
(p<0.03, and p<0.02, respectively; Fig. 4A ). Furthermore, in HT-29 xenografts, PS reduced TrxR activity by 40% (p<0.02) and TrxR levels determined immunohistochemically by 55% (p<0.01; Fig. 4C ).
Phospho-NSAIDs inhibit the activation of NF-κB
To further assess the biological relevance of the induction of oxidative stress by phospho-NSAIDs, we explored their effect on an intracellular redox-dependent signaling pathway. Thus we analyzed their effect on NF-κB, whose transcriptional activity is sensitive to redox changes (37) . NF-κB modulates tumor cell growth, with the outcome depending on biological context (38) .
In vitro all five compounds inhibited NF-κB activation determined by the electrophoretic mobility shift assay (EMSA) in MDA-MB-231 breast cancer cells (Fig. 5A) . A similar inhibitory effect was observed in vivo; we assessed in xenografts NF-κB activation by determining immunohistochemically the levels of pp65 (Fig. 5B) . As shown in Table 2C, As might be anticipated, tumor growth inhibition by these compounds is associated with a cytokinetic effect. All phospho-NSAIDs induced apoptosis and inhibited proliferation to a quantitatively significant but varying degree; neither effect, however, appeared dominant. Of interest, our cell culture studies mirror to some extent the in vivo cytokinetic effect of these compounds.
A key feature of the mechanism of action of phospho-NSAIDs was their ability to induce oxidative stress. This effect was noted in both cultured cells and animals. In cultured cells, the induction of oxidative stress levels was significant, concentration-dependent and inhibitable by the antioxidant NAC.
Again, there were individual variations, depending on the cell line and the compound. In animals, oxidative stress was assayed by the urinary levels of F2-isoprostane. This metabolite of PGF2α provides a validated measure of oxidative stress in the animal over some period of time (usually hours). As we have demonstrated recently, in the case of PI, the xenograft is indeed the source of the increased F2-isoprostane (41). Thus we can extrapolate that the oxidative stress that we observed in these studies originated in the xenografts. The induction of oxidative stress by the phospho-NSAIDs was a consequential event. There is a clear association between oxidative stress and cytokinetic changes (enhanced apoptosis, suppressed proliferation) both in vitro and, importantly, in vivo. To a first approximation, these changes underlie the tumor inhibitory effect of these compounds, making the redox homeostatic mechanism their prime molecular target.
Although cell signaling tends to be complex, the effect of the phospho-NSAIDs on the NF-кB pathway illustrates a possible link between drug-induced oxidative stress and cancer growth inhibition. It is conceivable that the anticancer effect of phosphor-NSAIDs is related in part to their redox effect on NF-кB, a prototypical redox-sensitive signaling pathway with relevance to cancer. Constitutive NF-κB activation is a hallmark of various types of cancer, including breast, colon and pancreatic (42) (43) (44) (45) . NF-κB, activated by oncogenes, carcinogens and inflammatory stimuli, promotes carcinogenesis and consequently has become a therapeutic target in cancer. When the strategically located Cys62 of NF-кB is oxidized, the NF-кB dimmer is rendered incapable of binding to DNA thus losing its extensive transcriptional effects. Phospho-NSAIDs inhibited NF-кB activation both in vitro and in vivo. This is a broader property of phospho-NSAIDs, which we recently showed to inhibit NF-κB activation in arthritisassociated inflammation (20) . It is plausible that the effect of phospho-NSAIDs mediates part of their anticancer effect.
Equally complex is the mechanism by which these compounds induce oxidative stress. The central role of ROS as an apoptotic trigger in response to phospho-NSAIDs was documented recently (41) . In the present work we focused on the thioredoxin system that consists of Trx, TrxR and NADPH. A pivotal component of cellular redox homeostasis, the thioredoxin system is involved in carcinogenesis and also (46) (47) (48) . When RONS oxidize a cellular protein, thioredoxin reduces it, being itself oxidized in the process; TrxR restores the oxidized Trx to its normal status.
Phospho-NSAIDs had a profound effect on the two protein members of this system, Trx-1 and TrxR. The expression of both was suppressed by phospho-NSAIDs and, in addition, the activity of TrxR (the only one of the two that was assayed for) was suppressed, generating a substantial cumulative effect. In only one case (HT-29 xenografts) the expression of Trx-1 was not suppressed by a phospho-NSAID (PS), but both the activity and expression of TrxR was suppressed, likely inactivating the thioredoxin system. Of note, PS did suppress Trx-1 expression in HT-29 xenografts treated under a different drug administration protocol (22) . It is, therefore, clear, that based on the role of the thioredoxin system this effect contributes to the induction of the all-important state of oxidative stress with its direct repercussion on tumor mass (loss of cells through apoptosis and dampened cell renewal). Indeed between the two, TrxR was the one that was suppressed the most by the phospho-NSAIDs. Consistently, we have shown in an effective combination study of P-S and DFMO that TrxR correlated with tumor growth, stressing the importance of the Trx system as a molecular target of these drugs (22) .
In conclusion, our findings indicate that these five phospho-NSAIDs, belonging to the broader pharmacological category of modified-NSAIDs, show strong anticancer efficacy and promising safety. Of particular interest is their shared ability to induce oxidative stress, an early event that appears to trigger cancer inhibitory cascades. Taken together, our data indicate that phospho-NSAIDs merit further evaluation as anticancer agents. A: Phospho-NSAIDs inhibit constitutive NF-κB activation. EMSA for NF-κB of nuclear fractions isolated from MDA-MB-231 cells after 4 h-treatment without or with each phospho-NSAID at 1.5xIC 50 . To determine the specificity of the NF-κB transcription factor-DNA complex, the control nuclear fraction was incubated in the presence of 100-fold molar excess of unlabeled oligonucleotide containing the consensus sequence for either the specific (+ NF-κB) or an unspecific (+ SP-1) transcription factor. A
